Is Opzelura Approved for Vitiligo?
Yes, Opzelura (ruxolitinib cream 1.5%) is FDA-approved for nonsegmental vitiligo in adults and children 12 years and older. The agency granted approval in October 2022 based on two phase 3 TRuE-V trials showing significant repigmentation: 30% of patients achieved at least 75% improvement in facial Vitiligo Area Scoring Index (F-VASI75) after 24 weeks, versus 10% on vehicle cream.[1]
How Does Opzelura Work for Vitiligo?
Opzelura is a JAK1/JAK2 inhibitor applied topically twice daily to depigmented skin. It blocks inflammatory signals that destroy melanocytes, promoting repigmentation from hair follicle reservoirs. Facial areas respond faster than body areas, with sustained effects up to 52 weeks in trials.[1][2]
Who Can Use It and What's the Dosing?
Prescribed for nonsegmental vitiligo (patchy, symmetric loss) on face, neck, arms, and trunk. Apply a pea-sized amount per affected area, up to 10% body surface. Not for segmental vitiligo or full-body use. Safe from age 12; pregnancy registry advised for reproductive-age patients.[1]
What Do Trial Results Show?
- Primary endpoint: 29.9% F-VASI75 at 24 weeks (TRuE-V1); 26.3% (TRuE-V2).[1]
- Long-term: 52.9% F-VASI75 at 52 weeks with continued use.[2]
- Patient-reported: 50% facial improvement by week 24 per Vitiligo Noticeability Scale.[1]
Real-world data mirrors trials, with 20-30% repigmentation in first months.[3]
Common Side Effects and Risks
Mild application-site acne (20%), itching (10%), redness (8%), fever (3%). Rare serious risks include infections or malignancy from JAK inhibition. Avoid with live vaccines; monitor for infections. Not for active skin infections.[1][4]
How Does It Compare to Other Vitiligo Treatments?
| Treatment | Mechanism | Repigmentation Rate | Use Case |
|-----------|-----------|---------------------|----------|
| Opzelura | Topical JAK inhibitor | 30% F-VASI75 (face, 24 weeks) | Nonsegmental, ages 12+ |
| Narrowband UVB | Phototherapy | 50-75% over 6-12 months | All types, clinic-based |
| Topical corticosteroids | Anti-inflammatory | 20-50% over months | Mild cases, risk of thinning |
| Calcineurin inhibitors (e.g., tacrolimus) | Immunosuppressant | 20-40% | Face, off-label |
Opzelura offers at-home convenience without skin atrophy, outperforming placebo but slower than phototherapy combos.[2][5]
Cost and Access
List price ~$2,300 for 60g tube (2-month supply); copay cards reduce to $0-$25 for insured. Covered by most plans for vitiligo. No generic yet; patent expires ~2036.[6][7]
When Might It Not Work or Be Avoided?
Fails in 50-70% for full-body response; combine with light therapy for better odds. Contraindicated in immunocompromised patients or active cancer. Black patients see similar efficacy despite higher baseline severity.[1][3]
[1]: FDA Label - Opzelura (ruxolitinib) cream. FDA.gov
[2]: Goldschmidt et al., Lancet (2022). PubMed
[3]: Ezzedine et al., J Am Acad Dermatol (2023). PubMed
[4]: Incyte prescribing info. Opzelura.com
[5]: Hamzavi et al., NEJM (2022). NEJM.org
[6]: GoodRx pricing data (2024). GoodRx.com
[7]: DrugPatentWatch - Ruxolitinib patents. DrugPatentWatch.com